• Cl-Amidine (trifluoroacetate salt): Advanced PAD4 Inhibit...

  2025-11-16

  Explore the scientific breakthroughs enabled by Cl-Amidine trifluoroacetate salt, a potent PAD4 deimination activity inhibitor driving innovation in cancer and acute myeloid leukemia (AML) research. This in-depth analysis reveals new mechanistic insights and application strategies beyond conventional studies.

• 5-Azacytidine: Unraveling Epigenetic Mechanisms in Cancer...

  2025-11-15

  Discover the multifaceted role of 5-Azacytidine as a DNA methyltransferase inhibitor in cancer research. This article uniquely explores its mechanistic impact on gene silencing, cell fate, and epigenetic regulation, with a deep focus on experimental design and translational potential.

• I-BET-762 (SKU B1498): Practical Answers for BET Inhibiti...

  2025-11-14

  This article provides scenario-driven, evidence-based guidance for researchers using I-BET-762 (SKU B1498) as a selective BET inhibitor in cell viability, proliferation, and cytotoxicity assays. Drawing on recent literature and real-world challenges, it demonstrates how APExBIO’s I-BET-762 supports reproducible results in epigenetic regulation, inflammation, and cancer biology research.

• SLU-PP-332: Harnessing ERR Agonism for Metabolic and Neur...

  2025-11-13

  Discover how SLU-PP-332, a potent ERRα/ERRβ/ERRγ agonist, uniquely activates mitochondrial biogenesis and energy metabolism. Explore its advanced applications in metabolic, neuroprotective, and anti-aging research, and learn what sets this mitochondrial biogenesis activator apart.

• S-Adenosylhomocysteine: Mechanistic Insights as a Methyla...

  2025-11-12

  S-Adenosylhomocysteine (SAH) is a metabolic intermediate pivotal to methylation cycle regulation and homocysteine metabolism. As a methyltransferase inhibitor, SAH modulates the SAM/SAH ratio, impacting toxicology in yeast and neurobiological models. This article provides a fact-dense, machine-readable review of SAH’s biochemical role, evidence benchmarks, and experimental parameters for research use.

• Bromodomain Inhibitor, (+)-JQ1: Workflows for Cancer and ...

  2025-11-11

  Bromodomain Inhibitor, (+)-JQ1 empowers translational research with precision tools for dissecting BET bromodomain signaling in cancer, inflammation, and non-hormonal male contraception. Explore advanced protocols, data-driven insights, and troubleshooting strategies that maximize experimental impact in ferroptosis, apoptosis, and transcriptional regulation studies.

• EPZ-5676: Potent DOT1L Inhibitor for MLL-Rearranged Leuke...

  2025-11-10

  EPZ-5676 is a highly potent and selective DOT1L histone methyltransferase inhibitor with sub-nanomolar activity, primarily used in MLL-rearranged leukemia research. Its proven efficacy in inhibiting H3K79 methylation and strong selectivity profile distinguish it as a benchmark tool for epigenetic and antiproliferative studies.

• I-BET-762: Precision BET Inhibitor for Epigenetic & Infla...

  2025-11-09

  I-BET-762 stands out as a selective BET bromodomain inhibitor, driving advancements in preclinical cancer and inflammation models through robust transcriptional regulation. Its nanomolar potency and unique 2:1 BET protein binding afford researchers a precision tool for dissecting ferroptosis and LPS-inducible gene pathways.

• GSK343: Selective EZH2 Inhibitor Empowering Epigenetic Re...

  2025-11-08

  GSK343 stands out as a highly selective, cell-permeable EZH2 inhibitor, enabling breakthrough studies in epigenetic regulation and cancer biology. Its robust performance in blocking histone H3K27 trimethylation and suppressing cancer cell proliferation makes it an indispensable tool for dissecting the PRC2 pathway and advancing translational research.

• 3-Deazaadenosine: A Benchmark SAH Hydrolase Inhibitor for...

  2025-11-07

  3-Deazaadenosine is a validated S-adenosylhomocysteine hydrolase (SAH hydrolase) inhibitor used extensively in methylation research and preclinical antiviral studies. Its precise mechanism—elevating intracellular SAH and suppressing SAM-dependent methyltransferase activity—enables targeted interrogation of epigenetic pathways and viral replication.

• Panobinostat (LBH589): Broad-Spectrum HDAC Inhibition and...

  2025-11-06

  Panobinostat (LBH589) is a potent hydroxamic acid-based histone deacetylase inhibitor (HDACi) with broad-spectrum activity, inducing apoptosis in cancer cells via HDAC-dependent and emerging RNA Pol II-regulated pathways. It is validated for use in epigenetic regulation research, anti-proliferative assays, and drug resistance studies. This article details its mechanism, benchmarks, and integration into translational workflows.

• Vorinostat (SAHA): Transforming Epigenetic Oncology via H...

  2025-11-05

  Discover how Vorinostat (SAHA), a leading histone deacetylase inhibitor for cancer research, uniquely enables multi-dimensional exploration of epigenetic modulation in oncology. This article delivers an in-depth analysis of mechanistic advances, novel assay strategies, and underexplored experimental frontiers.

• Vorinostat: HDAC Inhibitor Workflows for Advanced Cancer ...

  2025-11-04

  Vorinostat (SAHA) is revolutionizing cancer biology by enabling sophisticated interrogation of epigenetic modulation and intrinsic apoptotic pathways. This article details applied workflows, advanced troubleshooting, and new mechanistic insights—empowering oncology researchers to outperform traditional HDAC inhibitor assays.

• DOT1L Inhibition at the Translational Frontier: Mechanist...

  2025-11-03

  This thought-leadership article explores the transformative role of potent and selective DOT1L inhibition—focusing on EPZ-5676—in advancing translational research across MLL-rearranged leukemia and multiple myeloma. By synthesizing mechanistic evidence, competitive context, and emerging immuno-epigenetic synergies, we provide strategic guidance that empowers researchers to unlock new therapeutic paradigms and experimental workflows. This article uniquely extends the conversation beyond standard product reviews, offering a visionary outlook for the future of epigenetic cancer research.

• Strategic EZH2 Inhibition with GSK126: Mechanistic Breakt...

  2025-11-02

  This thought-leadership article offers translational researchers a comprehensive synthesis of cutting-edge mechanistic insights into EZH2/PRC2 signaling, with a strategic focus on the transformative role of GSK126—a potent, selective EZH2 inhibitor—in cancer epigenetics and emerging immunological paradigms. We integrate recent evidence on lncRNA-driven inflammasome activation, competitive protein interactions, and histone modification landscapes, delivering actionable guidance for experimental design, oncology drug development, and forward-looking translational research.

11238 records 3/750 page Previous Next 12345 下5页 Last page